Sarepta Therapeutics (SRPT) Posts Smaller-than-Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Sarepta Therapeutics (SRPT) PT Lowered to $168 at Piper Jaffray on 3Q Report; Lower Projected Enterprise Value Due to 'Eventual Cannibalization by DMD GeneRx'
October 25, 2018 7:54 AM EDTPiper Jaffray analyst Edward Tenthoff lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $168.00 (from $189.00) while maintaining a Overweight rating, following the company's third quarter earnings report.
Analyst Tenthoff notes a lowered outlook on SRPT shares on a "lower projected enterprise... More
Sarepta Therapeutics (SRPT) PT Lowered to $190 at RBC Capital
October 25, 2018 7:30 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $190.00 (from $200.00) while maintaining a Outperform rating.
The analyst commented, "With Exondys 51 meeting expectations and the company continuing to execute on multiple clinical gene therapy and RNA development... More
